Ascletis Pharma Inc. (Ascletis-B) reported a sharp increase in its interim net loss as aggressive investment in obesity and metabolic-disease research lifted R&D expenses by 132.7%.
Financials • Total income for the six months to 30 June 2026 fell 48.9% year on year (YoY) to RMB 53.0 million, mainly reflecting lower one-off government grants and smaller gains on equity investments. • R&D expenditure soared to RMB 341.66 million, up from RMB 146.81 million a year earlier, driven by multiple late-stage clinical programmes. • Administrative costs declined 28.9% YoY to RMB 30.80 million after staff-related savings. • Net loss attributable to shareholders expanded 263.5% YoY to RMB 319.67 million (≈ RMB 0.32 billion). • Basic and diluted loss per share widened to RMB 30.74 cents from RMB 9.14 cents.
Liquidity and Capital Structure • Cash, cash equivalents, deposits and other liquid investments totalled RMB 2.31 billion at 30 June 2026, up from RMB 1.83 billion a year earlier, underpinning operations into 2029. • A February 2026 share placement raised net proceeds of HKD 835.2 million (≈ RMB 0.74 billion), lifting share capital and share premium. • Current ratio stood at 12.9 (end-2025: 15.1); gearing remained low at 7.4%.
Operational Highlights Metabolic-disease pipeline expansion dominated the period: • Lead oral GLP-1R agonist ASC30 entered global Phase III trials (AURORA-1/2) in approximately 4,600 obese/overweight participants; first patient dosed and topline data expected Q3 2028. • ASC30 Phase II diabetes study completed enrolment; results due Q3 2026. • IND submissions planned in 2H 2026 for five additional obesity candidates, including first-in-class oral SARA ASC39 and multiple small-molecule and peptide fixed-dose combinations. • FDA IND clearances obtained for monthly/quarterly peptide candidates ASC36, ASC35 and dual combo ASC36_35FDC; pharmacokinetic data expected by end-2026/early-2027. • Decision to focus resources on metabolic diseases; the company is seeking partners for three immune-disease assets (ASC50/51/52).
Outlook for H2 2026 Management targets eleven clinical or regulatory milestones, including multiple IND filings, initiation of Phase I trials for oral ASC36 and IND submissions for triple and quadruple agonist peptides. The company reiterates that current liquidity is sufficient to support operations through 2029, encompassing planned NDA and MAA submissions for ASC30.
Other Developments • Ascletis maintains manufacturing capability at its 17,000 m² facility in Shaoxing, Zhejiang. • The ITC affirmed a US$0.57 million sanction in the Viking patent dispute; no provisions have been taken for the parallel US District Court case, which remains ongoing. • No interim dividend was declared.
Ascletis continues to prioritize rapid advancement of its obesity and metabolic-disease portfolio while preserving a robust balance sheet to fund late-stage clinical programmes.
Comments